Endocannabinoid System Research: Evidence-Based Cannabis Care for Older Adults with Pain, Sleep, and Mental Health Issues
Clinical Takeaway
Older adults are increasingly turning to edible cannabis products to manage pain, sleep difficulties, and mental health concerns, with cannabinoid profile playing a key role in product selection. Understanding what drives these choices helps clinicians have more informed conversations with older patients who are already using or considering cannabis.
#27 Edible Cannabis and Pain, Sleep, and Mental Health Management in Older Adults.
Citation: Delaney Rebecca K et al.. Edible Cannabis and Pain, Sleep, and Mental Health Management in Older Adults.. JAMA network open. 2026. PMID: 42101836.
Design: 0 Journal: 4 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
- Convenience sampling — generalizability limited
Abstract: IMPORTANCE: Older adults are the fastest-growing group of cannabis consumers in the US, seeking relief from age-related ailments (eg, pain or difficulty sleeping) and improved quality of life. However, little is known about the motivations and factors that influence their use of edible cannabis and product choice. OBJECTIVES: To explore the motivations of older adults in Colorado purchasing edible cannabis products to improve sleep, pain, or mental health concerns, and to understand how they perceive the benefits and drawbacks of different cannabinoid profiles: cannabidiol (CBD)-dominant, tetrahydrocannabinol (THC)-dominant, or a THC-CBD combination product. DESIGN, SETTING, AND PARTICIPANTS: This community-based, qualitative study was study conducted in Colorado from November 2021 to November 2023 as part of a larger clinical trial. Individual interviews were audio-recorded, transcribed, and analyzed. Participants were a convenience sample of adults aged 60 years or older who were interested in using edible cannabis for sleep, pain, or mental health symptoms. Participants completed an in-person interview prior to purchasing 1 of 3 edible product types. EXPOSURE: Use of edible cannabis products. MAIN OUTCOMES AND MEASURES: The primary outcomes were self-reported motivations for cannabis use and perceived benefits and drawbacks of different cannabinoid profiles, assessed through semistructured interviews conducted before product purchase. RESULTS: Among 169 participants (mean [SD] age, 70.8 [5.8] years, 89 female [54%]), 96 (57.5%) selected a THC and CBD combination product, 48 (28.7%) selected a CBD-dominant product, and 23 (13.8%) selected a THC-dominant product. Primary motivations for cannabis use included avoiding pharmaceuticals, exhausting other options, new or increasing problems, and evidence or claims of benefits. Evidence or claims of associated outcomes were seen as a benefit for all 3 product types. The most common drawback for THC and combination produc
What This Study Teaches Us
Older adults seeking cannabis for pain, sleep, or mood are most likely to choose combination THC/CBD products (57.5%) over CBD-alone or THC-alone, and their primary driver is avoiding or replacing pharmaceutical medications. This preference pattern emerges before actual use, reflecting either educated choice or unmet expectations from conventional treatments.
Why This Matters Clinically
Clinicians managing older adults increasingly encounter cannabis as a patient option or reality. Understanding that most gravitate toward balanced products, and that pharmaceutical avoidance is the leading motivator, helps frame conversations about efficacy, drug interactions, fall risk, and whether cannabis is filling a genuine gap or replacing treatments that may still be warranted.
Study Snapshot
| Study Design | Qualitative, community-based study using semistructured interviews before product selection |
| Population | 169 older adults (mean age 71 years, 54% female) in Colorado, interested in edible cannabis for sleep, pain, or mental health |
| Intervention | Participants chose one of three edible product types: CBD-dominant, THC-dominant, or THC/CBD combination. No dosing details specified. Interviews conducted pre-purchase from November 2021 to November 2023 |
| Primary Outcome | Self-reported motivations for cannabis use and perceived benefits/drawbacks of different cannabinoid profiles, assessed via interview |
| Key Result | 57.5% selected THC/CBD combination, 28.7% selected CBD-dominant, 13.8% selected THC-dominant. Primary motivations included avoiding pharmaceuticals and exhausting other options |
Where This Paper Deserves Skepticism
This is a qualitative preference study, not an outcomes trial, so it tells us what older adults choose and say they want, not whether their choices actually work or compare favorably to alternatives. The abstract cuts off mid-sentence on motivations, leaving incomplete data. Colorado is a legal, retail cannabis state with easy access and product information, so these motivations and preferences may not generalize to states with limited supply, higher cost, or less education. Convenience sampling introduces selection bias toward older adults already interested enough to volunteer. No follow-up data on actual efficacy, side effects, or whether perceived benefits match real outcomes.
Dr. Caplan’s Take
What I see here is older adults voting with their feet, and the majority are picking balanced products. That’s interesting and worth taking seriously in conversation with patients. The avoidance of pharmaceuticals is the headline finding, but the abstract doesn’t distinguish between people who tried and failed standard treatments versus those who decided a priori to avoid drugs. That’s a crucial clinical distinction I’d want to understand better before assuming everyone walking into this preference study has exhausted rational alternatives. This study is a useful window into what older adults think they want, not proof of what they should get or what works for them.
Clinical Bottom Line
Older adults in cannabis-legal areas prefer balanced THC/CBD products over single-cannabinoid options, and pharmaceutical avoidance is their primary motivator. Clinicians should ask whether that avoidance reflects legitimate treatment failure or premature abandonment of evidence-based care.
| |
Have thoughts on this? Share it:
